These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 27560521

  • 1. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
    Muhammad S, Planz O, Schwaninger M.
    Cerebrovasc Dis Extra; 2016; 6(2):50-9. PubMed ID: 27560521
    [Abstract] [Full Text] [Related]

  • 2. Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism.
    Mühl D, Ghosh S, Uzuelli JA, Lantos J, Tanus-Santos JE.
    Thromb Res; 2010 Jun; 125(6):549-53. PubMed ID: 20307903
    [Abstract] [Full Text] [Related]

  • 3. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
    Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ.
    Neurology; 2006 May 23; 66(10):1550-5. PubMed ID: 16717217
    [Abstract] [Full Text] [Related]

  • 4. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
    Tsuruoka A, Atsumi C, Mizukami H, Imai T, Hagiwara Y, Hasegawa Y.
    J Stroke Cerebrovasc Dis; 2014 May 23; 23(10):2894-2899. PubMed ID: 25282183
    [Abstract] [Full Text] [Related]

  • 5. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats.
    Sumii T, Lo EH.
    Stroke; 2002 Mar 23; 33(3):831-6. PubMed ID: 11872911
    [Abstract] [Full Text] [Related]

  • 6. Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
    Copin JC, Bengualid DJ, Da Silva RF, Kargiotis O, Schaller K, Gasche Y.
    Eur J Neurosci; 2011 Oct 23; 34(7):1085-92. PubMed ID: 21895804
    [Abstract] [Full Text] [Related]

  • 7. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death.
    Inzitari D, Giusti B, Nencini P, Gori AM, Nesi M, Palumbo V, Piccardi B, Armillis A, Pracucci G, Bono G, Bovi P, Consoli D, Guidotti M, Nucera A, Massaro F, Micieli G, Orlandi G, Perini F, Tassi R, Tola MR, Sessa M, Toni D, Abbate R, MAGIC Study Group.
    Stroke; 2013 Oct 23; 44(10):2901-3. PubMed ID: 23908067
    [Abstract] [Full Text] [Related]

  • 8. Extension of the thrombolytic time window with minocycline in experimental stroke.
    Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH.
    Stroke; 2008 Dec 23; 39(12):3372-7. PubMed ID: 18927459
    [Abstract] [Full Text] [Related]

  • 9. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.
    Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S.
    Stroke; 2003 Sep 23; 34(9):2165-70. PubMed ID: 12907822
    [Abstract] [Full Text] [Related]

  • 10. YangXueQingNaoWan attenuated blood brain barrier disruption after thrombolysis with tissue plasminogen activator in ischemia stroke.
    Yao SQ, Ye Y, Li Q, Wang XY, Yan L, Huo XM, Pan CS, Fu Y, Liu J, Han JY.
    J Ethnopharmacol; 2024 Jan 10; 318(Pt B):117024. PubMed ID: 37572928
    [Abstract] [Full Text] [Related]

  • 11. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
    Ishiguro M, Kawasaki K, Suzuki Y, Ishizuka F, Mishiro K, Egashira Y, Ikegaki I, Tsuruma K, Shimazawa M, Yoshimura S, Iwama T, Hara H.
    Neuroscience; 2012 Sep 18; 220():302-12. PubMed ID: 22710066
    [Abstract] [Full Text] [Related]

  • 12. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene.
    Montaner J, Fernández-Cadenas I, Molina CA, Monasterio J, Arenillas JF, Ribó M, Quintana M, Chacón P, Andreu AL, Alvarez-Sabín J.
    Stroke; 2003 Dec 18; 34(12):2851-5. PubMed ID: 14605329
    [Abstract] [Full Text] [Related]

  • 13. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis.
    Kelly MA, Shuaib A, Todd KG.
    Exp Neurol; 2006 Jul 18; 200(1):38-49. PubMed ID: 16624294
    [Abstract] [Full Text] [Related]

  • 14. Influenza virus infection aggravates stroke outcome.
    Muhammad S, Haasbach E, Kotchourko M, Strigli A, Krenz A, Ridder DA, Vogel AB, Marti HH, Al-Abed Y, Planz O, Schwaninger M.
    Stroke; 2011 Mar 18; 42(3):783-91. PubMed ID: 21293018
    [Abstract] [Full Text] [Related]

  • 15. Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
    Allahtavakoli M, Amin F, Esmaeeli-Nadimi A, Shamsizadeh A, Kazemi-Arababadi M, Kennedy D.
    Basic Clin Pharmacol Toxicol; 2015 Nov 18; 117(5):335-9. PubMed ID: 25899606
    [Abstract] [Full Text] [Related]

  • 16. Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway.
    Won S, Lee JH, Wali B, Stein DG, Sayeed I.
    J Cereb Blood Flow Metab; 2014 Jan 18; 34(1):72-80. PubMed ID: 24045404
    [Abstract] [Full Text] [Related]

  • 17. Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
    Zarisfi M, Allahtavakoli F, Hassanipour M, Khaksari M, Rezazadeh H, Allahtavakoli M, Taghavi MM.
    Brain Res Bull; 2017 Sep 18; 134():85-90. PubMed ID: 28710023
    [Abstract] [Full Text] [Related]

  • 18. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.
    Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, Quintana M, Alvarez-Sabín J.
    Circulation; 2003 Feb 04; 107(4):598-603. PubMed ID: 12566373
    [Abstract] [Full Text] [Related]

  • 19. Fibrinogen decrease after intravenous thrombolysis in ischemic stroke patients is a risk factor for intracerebral hemorrhage.
    Vandelli L, Marietta M, Gambini M, Cavazzuti M, Trenti T, Cenci MA, Casoni F, Bigliardi G, Pentore R, Nichelli P, Zini A.
    J Stroke Cerebrovasc Dis; 2015 Feb 04; 24(2):394-400. PubMed ID: 25497721
    [Abstract] [Full Text] [Related]

  • 20. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
    Liu W, Hendren J, Qin XJ, Liu KJ.
    Stroke; 2009 Jul 04; 40(7):2526-31. PubMed ID: 19478225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.